Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with this rare, potentially life‑threatening disorder.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution.

Icatibant Fresenius is used to target the bradykinin‑mediated pathway that underlies hereditary angioedema attacks.

- Hereditary angioedema type I: provides rapid reduction of swelling and pain during acute attacks. - Hereditary angioedema type II: delivers prompt symptom relief by blocking bradykinin effects. - Hereditary angioedema with normal C1‑INH: offers effective control of swelling episodes in patients lacking functional C1 inhibitor.

Icatibant Fresenius may be associated with a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema around the needle area. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate head discomfort. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or angioedema. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count observed in rare cases. - Acute pulmonary edema: rare fluid accumulation in lungs.

Before using Icatibant Fresenius, several safety considerations should be observed. - Assess severity of attack: confirm that the episode requires pharmacologic intervention. - Monitor for hypersensitivity: observe patient for signs of allergic reaction after injection. - Use under medical supervision: administration should be performed by trained healthcare personnel. - Contraindication in known hypersensitivity: avoid in patients with documented allergy to icatibant or its excipients. - Pregnancy and lactation: exercise caution as safety data are limited; weigh benefits against potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines that influence the bradykinin pathway or affect its pharmacodynamics.

Major Interactions (Avoid): - ACE inhibitors: concurrent use can increase bradykinin levels and diminish therapeutic effect. - Angiotensin‑converting enzyme (ACE)–derived drugs: may potentiate bradykinin‑related adverse events.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may alter bradykinin metabolism, requiring observation. - DPP‑4 inhibitors: potential additive effects on bradykinin activity. - Other B2 receptor antagonists: combined use may increase risk of hypotension.